ZHONGHENG GROUP(SH:600252) Zheng Quan Zhi Xing·2025-08-04 16:36Summary of Key Points Core Viewpoint - Guangxi Wuzhou Zhongheng Group Co., Ltd. has acquired a patent for a drug technology aimed at treating chronic heart failure through its wholly-owned subsidiary, Zhongheng Innovation, for a total price of RMB 55 million [1][2][3]. Transaction Overview - The acquisition involves a drug technology (patent) for treating chronic heart failure, with the transaction price set at RMB 55 million, excluding tax [1][3]. - The transaction has been approved by the company's board of directors and does not require shareholder approval [1][3]. - The contract was signed on August 1, 2025, following the receipt of qualification confirmation from the Shanghai Technology Exchange [2][3]. Transaction Details - The project was publicly listed for transfer on May 20, 2025, with a minimum bid price of RMB 55 million and a deposit of RMB 500,000 [3]. - Payment for the transfer will be made in stages, with an initial payment of at least RMB 5 million due within 10 working days after the contract takes effect [3][6]. Drug Technology Information - The drug, referred to as LZ-01, is a novel compound discovered by the Navy Medical University of the People's Liberation Army, which significantly improves myocardial energy metabolism and heart function in chronic heart failure patients [5][6]. - The drug is classified as a Class 1 innovative chemical drug, administered orally, and is currently in the preclinical research phase [6]. Impact on the Company - This acquisition aligns with the company's strategic focus on unmet clinical needs and potential markets, particularly in cardiovascular and metabolic diseases [8]. - The transaction is expected to enhance the company's product line and market competitiveness without significantly impacting its short-term financial performance [8].